CHEUNG ANTHONY TZEYEW

Chief Scientific Officer at enGene Therapeutics Inc. · on record since Oct 31, 2023

Insider trading activity of CHEUNG ANTHONY TZEYEW

Transactions on record: 14; since Nov 2, 2023

Open-market buys: 0

Open-market sells: 0

Companies traded: 1; last filing Feb 3, 2026

Figures computed from official regulatory filings — .

Companies where CHEUNG ANTHONY TZEYEW has traded

enGene Therapeutics Inc.14 tx · $47.1K · Feb 3, 2026

Track record of CHEUNG ANTHONY TZEYEW

Insufficient history for a statistical track record (fewer than 5 open-market buys).

Transaction history of CHEUNG ANTHONY TZEYEW

Co-insiders of CHEUNG ANTHONY TZEYEW

Astley-Sparke PhilipenGene Therapeutics Inc.
BIOTECHNOLOGY VALUE FUND II LPenGene Therapeutics Inc.
BIOTECHNOLOGY VALUE FUND L PenGene Therapeutics Inc.
Biotechnology Value Trading Fund OS LPenGene Therapeutics Inc.
Bos JasperenGene Therapeutics Inc.
Boyd Matthew RossenGene Therapeutics Inc.
BRUNK GERALD AenGene Therapeutics Inc.
BRYCE RICHARD PAULenGene Therapeutics Inc.
Buck JillenGene Therapeutics Inc.
BVF GP HOLDINGS LLCenGene Therapeutics Inc.
BVF I GP LLCenGene Therapeutics Inc.
BVF II GP LLCenGene Therapeutics Inc.
BVF INC/ILenGene Therapeutics Inc.
BVF PARTNERS L P/ILenGene Therapeutics Inc.
BVF Partners OS Ltd.enGene Therapeutics Inc.
Chinoporos ConstantineenGene Therapeutics Inc.
Connolly JoanenGene Therapeutics Inc.
Cooper Ronald Harold WilfredenGene Therapeutics Inc.
Daws D. RyanenGene Therapeutics Inc.
FONDS DE SOLIDARITE DES TRAVAILLEURS DU QUEBECenGene Therapeutics Inc.
Forbion Capital Fund III Cooperatief U.A.enGene Therapeutics Inc.
Forbion Growth Management B.V.enGene Therapeutics Inc.
Forbion Growth Opportunities Fund I Cooperatief U.A.enGene Therapeutics Inc.
Forbion Growth Sponsor FEAC I B.V.enGene Therapeutics Inc.
Forbion III Management B.V.enGene Therapeutics Inc.
Giguere LeeenGene Therapeutics Inc.
Glickman Richard MenGene Therapeutics Inc.
Grassin Alexandre Jean-Rene ErwanenGene Therapeutics Inc.
Grossman WilliamenGene Therapeutics Inc.
Hanson Jason DavidenGene Therapeutics Inc.
HASTINGS PAUL JenGene Therapeutics Inc.

This page republishes public regulatory disclosures.

Company	Filed	Type	Qty	Price	Value · USD	Src
enGene Therapeutics Inc.Listing on record	Feb 3, 2026	AwardD (derivative)	195,000	0.00 USD	n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise))	SEC
enGene Therapeutics Inc.Listing on record	Jan 31, 2025	AwardD (derivative)	250,000	0.00 USD	n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise))	SEC
enGene Therapeutics Inc.Listing on record	Oct 22, 2024	AwardD (derivative)	100,000	0.00 USD	n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise))	SEC
enGene Therapeutics Inc.Listing on record	Mar 20, 2024	ExerciseD (derivative)	-52,940	0.00 USD	n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise))	SEC
enGene Therapeutics Inc.Listing on record	Mar 20, 2024	Exercise	52,940	0.89 USD	$47.1K	SEC
enGene Therapeutics Inc.Listing on record	Nov 2, 2023	Award	49,933	—	n/a (No price was disclosed in the filing)	SEC
enGene Therapeutics Inc.Listing on record	Nov 2, 2023	AwardD (derivative)	185,222	—	n/a (No price was disclosed in the filing)	SEC
enGene Therapeutics Inc.Listing on record	Nov 2, 2023	AwardD (derivative)	2,255	—	n/a (No price was disclosed in the filing)	SEC
enGene Therapeutics Inc.Listing on record	Nov 2, 2023	AwardD (derivative)	1,266	—	n/a (No price was disclosed in the filing)	SEC
enGene Therapeutics Inc.Listing on record	Nov 2, 2023	AwardD (derivative)	155,472	—	n/a (No price was disclosed in the filing)	SEC
enGene Therapeutics Inc.Listing on record	Nov 2, 2023	AwardD (derivative)	36,618	—	n/a (No price was disclosed in the filing)	SEC
enGene Therapeutics Inc.Listing on record	Nov 2, 2023	AwardD (derivative)	52,940	—	n/a (No price was disclosed in the filing)	SEC
enGene Therapeutics Inc.Listing on record	Nov 2, 2023	AwardD (derivative)	28,876	—	n/a (No price was disclosed in the filing)	SEC
enGene Therapeutics Inc.Listing on record	Nov 2, 2023	AwardD (derivative)	22,860	—	n/a (No price was disclosed in the filing)	SEC

Company	Filed	Type	Qty	Price	Value · USD	Src
enGene Therapeutics Inc.Listing on record	Feb 3, 2026	AwardD (derivative)	195,000	0.00 USD	n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise))	SEC
enGene Therapeutics Inc.Listing on record	Jan 31, 2025	AwardD (derivative)	250,000	0.00 USD	n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise))	SEC
enGene Therapeutics Inc.Listing on record	Oct 22, 2024	AwardD (derivative)	100,000	0.00 USD	n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise))	SEC
enGene Therapeutics Inc.Listing on record	Mar 20, 2024	ExerciseD (derivative)	-52,940	0.00 USD	n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise))	SEC
enGene Therapeutics Inc.Listing on record	Mar 20, 2024	Exercise	52,940	0.89 USD	$47.1K	SEC
enGene Therapeutics Inc.Listing on record	Nov 2, 2023	Award	49,933	—	n/a (No price was disclosed in the filing)	SEC
enGene Therapeutics Inc.Listing on record	Nov 2, 2023	AwardD (derivative)	185,222	—	n/a (No price was disclosed in the filing)	SEC
enGene Therapeutics Inc.Listing on record	Nov 2, 2023	AwardD (derivative)	2,255	—	n/a (No price was disclosed in the filing)	SEC
enGene Therapeutics Inc.Listing on record	Nov 2, 2023	AwardD (derivative)	1,266	—	n/a (No price was disclosed in the filing)	SEC
enGene Therapeutics Inc.Listing on record	Nov 2, 2023	AwardD (derivative)	155,472	—	n/a (No price was disclosed in the filing)	SEC
enGene Therapeutics Inc.Listing on record	Nov 2, 2023	AwardD (derivative)	36,618	—	n/a (No price was disclosed in the filing)	SEC
enGene Therapeutics Inc.Listing on record	Nov 2, 2023	AwardD (derivative)	52,940	—	n/a (No price was disclosed in the filing)	SEC
enGene Therapeutics Inc.Listing on record	Nov 2, 2023	AwardD (derivative)	28,876	—	n/a (No price was disclosed in the filing)	SEC
enGene Therapeutics Inc.Listing on record	Nov 2, 2023	AwardD (derivative)	22,860	—	n/a (No price was disclosed in the filing)	SEC